Tyrphostins and retinoids cooperate during inhibition of in vitro growth of ovarian cancer cells.
Thomas W Grunt
Index: Cancer Lett. 189(2) , 147-56, (2003)
Full Text: HTML
Abstract
Chemoresistance of ovarian cancer can be overcome by co-administration of retinoids, albeit clinical proof of this hypothesis is pending. Moreover, growth factor/c-erbB signaling is crucial for ovarian tumor growth/chemosensitivity. Retinoids and c-erbB modulators therefore represent promising drugs for ovarian cancer. We demonstrate that c-erbB-1 (RG-14620, AG1517) and c-erbB-2 selective tyrphostins (AG825, AG879), and all-trans and 9-cis retinoic acid inhibit ovarian cancer cell proliferation (HOC-7, OVCAR-3). Unlike retinoids, AG1517 and AG879 induce apoptosis. The antiproliferative activity of AG1517 is enhanced by all-trans retinoic acid suggesting that c-erbB and retinoid pathways interact. Thus, these agents cooperate during ovarian cancer cell growth inhibition.
Related Compounds
Related Articles:
Photoinstability of some tyrphostin drugs: chemical consequences of crystallinity.
1995-11-01
[Pharm. Res. 12(11) , 1708-15, (1995)]
2007-06-01
[J. Cell Physiol. 211(3) , 803-15, (2007)]
2009-09-01
[Zhonghua Fu Chan Ke Za Zhi 44(9) , 681-5, (2009)]
1995-12-01
[J. Surg. Res. 59(6) , 675-80, (1995)]
1994-01-01
[Drug Metab. Dispos. 22(2) , 216-23, (1994)]